BioSpace News Archive

Biosimilars are medicines that mainly constitute proteins and resemble biological drugs in structure as well as function. The total potential savings obtained from the consistent use of biosimilars in addressing the rising public health consumer needs was anticipated to cross USD 100 billion in annual value by 2020.

The global hemophilia treatment market is expected to accumulate considerable returns in the coming years due to the growing cases of genetic abnormalities as well as the prevalence of hemophilia. Hemophilia is a rare bleeding condition, that leads to prolonged bleeding after an injury or a surgery owing to a delay in blood clotting.

Increasing prevalence of obesity among adults along with rising sedentary lifestyle are anticipated to drive bariatric surgery devices market size.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the “November Warrants”), that were issued on November 1, 2019.

Initial agreement provides up to 40 million doses to COVAX in 2021 First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility structure

Exelixis Announces U.S. FDA Approval of CABOMETYX ® (cabozantinib) in Combination with OPDIVO ® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

ATVenture Center, LLC, announced today that its Sanatela cancer biotechnology subsidiary has moved into a 2,000 square foot clean room space in Fairport, NY and will begin ramping up production of the Sanatela MatrixTM, an advanced biomaterial that can be used as a tool for early cancer detection and treatment.

Coherus BioSciences, Inc., announced that effective January 21, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares of the common stock of the Company to 3 newly hired non-officer employees, with a per share exercise price of $17.99, the closing trading price on the grant date.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President of Quanterix, and Founder, Powering Precision Health, Kevin Hrusovsky will present at PMWC 2021 COVID-19 Conference being held Jan. 25-27, 2021

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a public offering price of $11.00 per share, which includes 600,000 shares issued upon the exercise in full by the underwriters of their option to purcha